Multi-center evaluation of GenoType MTBDRsl line probe assay for rapid detection of pre-XDR and XDR Mycobacterium tuberculosis in China

Objectives: The implementation of rapid and reliable drug susceptibilities diagnosis is fundamental for effective treatment of multidrug-resistant tuberculosis(MDR-TB). The present study aimed to assess the diagnostic performance of the 2nd-version GenoType MTBDRsl kit as well as the impact of its implementation on the turnaround time in a multi-center Chinese study. Methods: Totally 353 MDR-TB patient specimens were consecutively tested. The 2nd-version GenoType MTBDRs1 assay, drug susceptibility testing with the MGIT 960 system, and sequencing were performed and compared. Results: MTBDRs1 testing identified the major genotypes associated with fluoroquinolones resistance, predominated by gyrA MUT3B (Asp94Asn and Asp94Tyr, 26.5%) and MUT3C (Asp94Gly, 19.5%). The genotypes associated with resistance to 2nd-line injectable drugs(SLIDs) were rrsMUT1(A1401G, 64.9%) and absence of WT1(C1402T, 10.5%). The sensitivities for detection of resistance to fluoroquinolones, SLIDs, and their combination (extensively drug resistance, XDR) were 80.5%, 80.7% and 73.5% and specificities were 100.0%, 99.3% and 99.1%, respectively. Implementation of this test significantly reduced the turnaround time between sample collection and result reporting from 45 to 3 days, a reduction by 93.3% (p, 0.001). Conclusion: With a favorable diagnostic performance and short turnaround time, the 2nd-version GenoType MTBDRs1 assay proves its value for early diagnosis of resistance to 2nd-line drugs as well as of XDR-TB in China. (C) 2018 The British Infection Association. Published by Elsevier Ltd. All rights reserved.